PE20142367A1 - Formulaciones de imiquimod - Google Patents

Formulaciones de imiquimod

Info

Publication number
PE20142367A1
PE20142367A1 PE2014000347A PE2014000347A PE20142367A1 PE 20142367 A1 PE20142367 A1 PE 20142367A1 PE 2014000347 A PE2014000347 A PE 2014000347A PE 2014000347 A PE2014000347 A PE 2014000347A PE 20142367 A1 PE20142367 A1 PE 20142367A1
Authority
PE
Peru
Prior art keywords
acid
formulations
imiquimod formulations
alcohol
imiquimod
Prior art date
Application number
PE2014000347A
Other languages
English (en)
Inventor
Michael T Nordsiek
Sharon F Levy
James H Lee
James H Kulp
Kodumudi S Balaji
Tze-Chiang Meng
Jason J Wu
Valyn S Bahm
Robert Babilon
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142367(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of PE20142367A1 publication Critical patent/PE20142367A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A FORMULACIONES DE IMIQUIMOD QUE COMPRENDEN EXCIPIENTES TALES COMO ACIDOS GRASOS, ALCOHOL CETILICO, ALCOHOL ESTEARILICO, VASELINA BLANCA, GLICERINA, GOMA XANTANA, METILPARABENO, ENTRE OTROS, DONDE EL ACIDO GRASO ES ACIDO LINOLEICO, ESTEARICO, PALMITICO, ISOESTEARICO, ENTRE OTROS. DICHAS FORMULACIONES SON UTILES EN EL TRATAMIENTO DE LA QUERATOSIS ACTINICA
PE2014000347A 2008-12-19 2009-12-18 Formulaciones de imiquimod PE20142367A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13953608P 2008-12-19 2008-12-19
US14473109P 2009-01-14 2009-01-14
US20514509P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
PE20142367A1 true PE20142367A1 (es) 2015-01-10

Family

ID=42316709

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014000347A PE20142367A1 (es) 2008-12-19 2009-12-18 Formulaciones de imiquimod
PE2009001323A PE20100469A1 (es) 2008-12-19 2009-12-18 Formulaciones de imiquimod

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2009001323A PE20100469A1 (es) 2008-12-19 2009-12-18 Formulaciones de imiquimod

Country Status (27)

Country Link
US (13) US20110021555A1 (es)
EP (1) EP2378876B1 (es)
AR (1) AR074802A1 (es)
AU (1) AU2009335943A1 (es)
BR (1) BRPI0923164A2 (es)
CL (1) CL2009002183A1 (es)
CO (1) CO6400171A2 (es)
CR (1) CR20110338A (es)
CY (1) CY1121485T1 (es)
DK (1) DK2378876T3 (es)
DO (1) DOP2011000195A (es)
EA (1) EA201100984A1 (es)
ES (1) ES2720149T3 (es)
GE (1) GEP20146198B (es)
HR (1) HRP20190306T1 (es)
HU (1) HUE041944T2 (es)
IL (2) IL213628A (es)
LT (1) LT2378876T (es)
MX (2) MX346455B (es)
PA (1) PA8855101A1 (es)
PE (2) PE20142367A1 (es)
PL (1) PL2378876T3 (es)
PT (1) PT2378876T (es)
RS (1) RS58566B1 (es)
SI (1) SI2378876T1 (es)
TW (1) TWI442923B (es)
WO (1) WO2010080345A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030089A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Transgenic plants with enhanced growth characteristics
US20110030104A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
ES2720149T3 (es) 2008-12-19 2019-07-18 Medicis Pharmaceutical Corp Formulaciones de imiquimod con un contenido de dosificación menor y regímenes de dosificación cortos para tratar queratosis actínica
EP2453747B1 (en) * 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
DK2584900T3 (en) 2010-06-25 2019-04-01 Medicis Pharmaceutical Corp Combination therapy with cryosurgery and low-dose imiquimod for the treatment of actinic keratosis
US9072876B2 (en) * 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
WO2013040447A2 (en) 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
EP2785336B1 (en) * 2011-11-30 2015-09-30 Merz Pharma GmbH & Co. KGaA Use of pegylated alcohols for the treatment of actinic keratosis
US10076535B2 (en) 2012-04-27 2018-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US9576445B2 (en) 2013-09-06 2017-02-21 Immersion Corp. Systems and methods for generating haptic effects associated with an envelope in audio signals
US9619980B2 (en) 2013-09-06 2017-04-11 Immersion Corporation Systems and methods for generating haptic effects associated with audio signals
US9711014B2 (en) 2013-09-06 2017-07-18 Immersion Corporation Systems and methods for generating haptic effects associated with transitions in audio signals
SG11201602361UA (en) * 2013-10-08 2016-04-28 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
KR102573972B1 (ko) * 2014-09-10 2023-09-01 워싱턴 유니버시티 전암성 피부 병변의 치료를 위한 조성물과 방법
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
US10617693B2 (en) * 2017-03-10 2020-04-14 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT610737A (es) 1955-11-18 1900-01-01
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (sv) 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
CZ20012446A3 (cs) 1999-01-08 2002-01-16 3M Innovative Properties Company Farmaceutický prostředek pro léčbu onemocnění sliznice
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
EP1401437A1 (en) 2001-06-15 2004-03-31 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
JP4447914B2 (ja) * 2001-11-29 2010-04-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節物質を含む医薬品
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
JP4891066B2 (ja) * 2003-03-13 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 皮膚の質を改善する方法
CA2518082C (en) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7521459B2 (en) * 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
US20090232755A1 (en) * 2003-07-28 2009-09-17 Leslie Baumann Combination therapies for treating photodamaged skin
CN1845736A (zh) 2003-09-02 2006-10-11 3M创新有限公司 治疗粘膜相关病症的方法
CN1922137A (zh) 2003-12-31 2007-02-28 太景生物科技股份有限公司 蛋白酶抑制剂
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
US20070196452A1 (en) 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (zh) 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105028A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
AU2006286497A1 (en) * 2005-08-31 2007-03-08 Serentis Limited Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with Staphylococcus aureus
US8703753B2 (en) * 2005-09-15 2014-04-22 Biomas Ltd. Use of tellurium compounds for the treatment of actinic keratosis
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US20070081962A1 (en) 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
US20070264317A1 (en) 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
ES2393761T3 (es) * 2006-07-14 2012-12-27 Stiefel Research Australia Pty Ltd Espuma farmacéutica de ácido graso
AU2007275815A1 (en) 2006-07-18 2008-01-24 Wirra Ip Pty. Ltd. Immune response modifier formulations
CA2659733A1 (en) 2006-07-31 2008-02-07 3M Innovative Properties Company Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
UA95975C2 (ru) * 2006-09-15 2011-09-26 Селджин Корпорэйшн N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения
JP5388854B2 (ja) * 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
JP5389668B2 (ja) * 2007-01-31 2014-01-15 チョンシー ユー 皮膚浸透率の非常に高い１Ｈ−イミダゾ［４，５−ｃ］キノリン−４−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
WO2008098232A1 (en) * 2007-02-08 2008-08-14 Graceway Pharmaceuticals, Llc Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
WO2008118765A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
CA2679067A1 (en) * 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en) 2007-05-08 2008-11-20 The Brigham And Women's Hospital, Inc Methods and products for treating proliferative disorders
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en) 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en) * 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
KR20100117077A (ko) 2008-01-15 2010-11-02 다우 파마슈티컬 사이언시즈, 인코포레이티드 이미퀴모드 제제
SG188104A1 (en) 2008-01-31 2013-03-28 Curevac Gmbh Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants
US20090246156A1 (en) * 2008-03-31 2009-10-01 Audrey Kunin Anti-acne sunscreen composition
CN102046180A (zh) * 2008-04-03 2011-05-04 同源3公司 用于免疫治疗的组合物和方法
WO2009134769A1 (en) 2008-04-28 2009-11-05 Novartis Ag Nanoparticles for use in pharmaceutical compositions
EP2303280A2 (en) 2008-05-30 2011-04-06 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
US20110212157A1 (en) 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2010050889A1 (en) 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
ES2720149T3 (es) * 2008-12-19 2019-07-18 Medicis Pharmaceutical Corp Formulaciones de imiquimod con un contenido de dosificación menor y regímenes de dosificación cortos para tratar queratosis actínica
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2453747B1 (en) 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US9072876B2 (en) * 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
WO2013040447A2 (en) * 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

Also Published As

Publication number Publication date
US20110263636A1 (en) 2011-10-27
US8236816B2 (en) 2012-08-07
AU2009335943A1 (en) 2013-10-24
BRPI0923164A2 (pt) 2016-01-26
CO6400171A2 (es) 2012-03-15
WO2010080345A1 (en) 2010-07-15
MX346455B (es) 2017-03-21
US20110263635A1 (en) 2011-10-27
TW201040173A (en) 2010-11-16
US20110257219A1 (en) 2011-10-20
US8222270B2 (en) 2012-07-17
TWI442923B (zh) 2014-07-01
EP2378876A1 (en) 2011-10-26
US20110021555A1 (en) 2011-01-27
PA8855101A1 (es) 2010-07-27
PE20100469A1 (es) 2010-07-31
DOP2011000195A (es) 2011-12-15
HRP20190306T1 (hr) 2019-05-03
MX2011001555A (es) 2011-04-14
IL255163A0 (en) 2017-12-31
PT2378876T (pt) 2019-03-01
CR20110338A (es) 2011-11-10
HUE041944T2 (hu) 2019-06-28
US20110263637A1 (en) 2011-10-27
US20200276182A1 (en) 2020-09-03
GEP20146198B (en) 2014-11-25
US20130210855A1 (en) 2013-08-15
AR074802A1 (es) 2011-02-16
US20110263634A1 (en) 2011-10-27
EP2378876A4 (en) 2012-12-05
US20110257218A1 (en) 2011-10-20
US20110257216A1 (en) 2011-10-20
US10238644B2 (en) 2019-03-26
EP2378876B1 (en) 2018-11-14
CY1121485T1 (el) 2020-05-29
ES2720149T3 (es) 2019-07-18
IL213628A (en) 2017-11-30
IL213628A0 (en) 2011-07-31
EA201100984A1 (ru) 2012-01-30
DK2378876T3 (en) 2019-03-11
US9370509B2 (en) 2016-06-21
PL2378876T3 (pl) 2019-06-28
US20110263633A1 (en) 2011-10-27
RS58566B1 (sr) 2019-05-31
US20160303111A1 (en) 2016-10-20
US11318130B2 (en) 2022-05-03
IL255163B (en) 2019-01-31
SI2378876T1 (sl) 2019-05-31
CL2009002183A1 (es) 2011-01-07
US20110257217A1 (en) 2011-10-20
US8299109B2 (en) 2012-10-30
LT2378876T (lt) 2019-04-25

Similar Documents

Publication Publication Date Title
PE20142367A1 (es) Formulaciones de imiquimod
CL2019002477A1 (es) Producción de ácidos graso poliinsaturados de cadena larga en células vegetales. (divisional solicitud 201403402)
CL2019002663A1 (es) Producción de ácidos grasos poliinsaturados de cadena larga en células vegetales. (divisional solicitud 201702448)
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
PE20080886A1 (es) Metodo para la produccion de semilla de maiz hibrido y composiciones producidas a partir del mismo
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
CO6420355A2 (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
CO6541606A2 (es) Espiroindolinona- pirrolidinas
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
CR20110686A (es) Pirimidinonas como ihnibidores de pi3k
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CL2016000905A1 (es) Disminución del contenido de ácidos grasos saturados de semillas de plantas (solicitud divisional de 3665-2012).
GT200600463A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
EA201390799A1 (ru) Триазолопиридины
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
EA201690854A1 (ru) Фармацевтические композиции с гидратирующим и смазывающим действием
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
ECSP10010293A (es) Aceite de girasol con elevada termoestabilidad
AR061646A1 (es) Profarmacos de penem
CL2011001539A1 (es) Compuestos derivados de un acido graso poliinsaturado omega 3 u omega 6 y un ester de diol con actividad anti-inflamatoria y antibacteriana; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento del acne o la dermatitis seborreica.
AR087879A1 (es) Composiciones para el tratamiento de ulceras perifericas de diversos origenes

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed